Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

Inflammation, Atherosclerosis, and Coronary Artery Disease

Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · see citing works

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · see citing works

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848 · see citing works

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · see citing works

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · see citing works

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · see citing works

Major lipids, apolipoproteins, and risk of vascular disease

The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731 · see citing works

Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women

Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · see citing works

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619 · see citing works

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443 · see citing works

Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease

Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115 · see citing works

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 933 · see citing works

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.

Graaf, J. D., Hak-Lemmers, H. L. M., Hectors, M. P. C., Demacker, P. N. M., Hendriks, J. C. M., & Stalenhoef, A. F. H. (1991) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.11.2.298 · Cited by 714 · see citing works

Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL

Navab, M., Ananthramaiah, G. M., Reddy, S. T., Lenten, B. J. V., Ansell, B. J., Fonarow, G. C., Vahabzadeh, K., Hama, S. Y., Hough, G., Kamranpour, N., et al. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400001-jlr200 · Cited by 687 · see citing works

Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality

Cui, Y. A., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., LANGENBERG, P. W., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 657 · see citing works

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men

Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514 · see citing works

The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARα Activation in Man

Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Åmark, P., Angelin, B., & Rudling, M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.014 · Cited by 512 · see citing works

Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study

Hoogeveen, R. C., Gaubatz, J. W., Sun, W., Dodge, R. C., Crosby, J. R., Jiang, J., Couper, D., Virani, S. S., Kathiresan, S., Boerwinkle, E., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303284 · Cited by 507 · see citing works

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction

Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501 · see citing works

Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ^|^mdash;2012 Version

Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., Egusa, G., Hiro, T., Hirobe, K., Iida, M., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.15792 · Cited by 468 · see citing works

The Forgotten Majority

Libby, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.006 · Cited by 388 · see citing works

Conversion of very low density lipoprotein to low density lipoprotein. A metabolic study of apolipoprotein B kinetics in human subjects.

Sigurdsson, G. T., Nicoll, A. D., & Lewis, B. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108229 · Cited by 308 · see citing works

HDL Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol Export

Du, X.-M., Kim, M., Hou, L., Goff, W. L., Chapman, M. J., Eck, M. V., Curtiss, L. K., Burnett, J. R., Cartland, S. P., Quinn, C. M., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.305485 · Cited by 303 · see citing works

Fibroblast Growth Factor 21 Controls Glycemia via Regulation of Hepatic Glucose Flux and Insulin Sensitivity

Berglund, E. D., Li, C. Y., Bina, H. A., Lynes, S. E., Michael, M. D., Shanafelt, A. B., Kharitonenkov, A., & Wasserman, D. H. (2009) · Endocrinology · doi:10.1210/en.2009-0221 · Cited by 297 · see citing works

New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study

Zhao, Y. Y., Weir, M. A., Manno, M., Cordy, P., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Moist, L., Parikh, C. R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00401 · Cited by 258 · see citing works

Combination lipid therapy in type 2 diabetes

(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245 · see citing works

Interplay between FGF21 and insulin action in the liver regulates metabolism

Emanuelli, B., Vienberg, S. G., Smyth, G., Cheng, C., Stanford, K. I., Arumugam, M., Michael, M. D., Adams, A. C., Kharitonenkov, A., & Kahn, C. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67353 · Cited by 243 · see citing works

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk

Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227 · see citing works

Fibroblast growth factor 21: from pharmacology to physiology

Kliewer, S. A., & Mangelsdorf, D. J. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28449b · Cited by 219 · see citing works

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208 · see citing works

Relation Among the Plasma Triglyceride/High-Density Lipoprotein Cholesterol Concentration Ratio, Insulin Resistance, and Associated Cardio-Metabolic Risk Factors in Men and Women

Salazar, M. R., Carbajal, H. A., Espeche, W. G., Sisnieguez, C. E. L., Balbín, E., Dulbecco, C. A., Aizpurúa, M., Marillet, A. G., & Reaven, G. M. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.02.016 · Cited by 195 · see citing works

Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control

Carey, V. J., Bishop, L. M., Laranjo, N., Harshfield, B. J., Kwiat, C., & Sacks, F. M. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.002 · Cited by 149 · see citing works

Fibrates for secondary prevention of cardiovascular disease and stroke

Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580.pub2 · Cited by 142 · see citing works

Cholesterol efflux and reverse cholesterol transport.

Favari, E., Chroni, A., Tietge, U., Zanotti, I., Escolà-Gil, J., & Bernini, F. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-09665-0_4 · Cited by 137 · see citing works

Small Dense Low-Density Lipoproteins Cholesterol can Predict Incident Cardiovascular Disease in an Urban Japanese Cohort: The Suita Study

Arai, H., Kokubo, Y., Watanabe, M., Sawamura, T., Ito, Y., Minagawa, A., Okamura, T., & Miyamato, Y. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14936 · Cited by 134 · see citing works

Identification of lipoproteins of intestinal origin in human atherosclerotic plaque

Pal, S., Semorine, K., Watts, G. F., & Mamo, J. (2003) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2003.120 · Cited by 107 · see citing works

Identification of Cardiometabolic Risk: Visceral Adiposity Index Versus Triglyceride/HDL Cholesterol Ratio

Salazar, M. R., Carbajal, H. A., Espeche, W. G., Aizpurúa, M., Maciel, P. M., & Reaven, G. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.10.012 · Cited by 93 · see citing works

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Taskinen, M., & Borén, J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0614-1 · Cited by 90 · see citing works

Cholesteryl Ester Hydroperoxide Lability Is a Key Feature of the Oxidative Susceptibility of Small, Dense LDL

Chancharme, L., Thérond, P., Nigon, F., Lepage, S., Couturier, M., & Chapman, M. J. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.3.810 · Cited by 80 · see citing works

Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy

Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Mazzone, T., Carlson, D. M., Williams, L. A., Kelly, M. T., Camp, H. S., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302926 · Cited by 63 · see citing works

Correlation of fasting serum apolipoprotein B‐48 with coronary artery disease prevalence

Masuda, D., Sugimoto, T., Tsujii, K., Inagaki, M., Nakatani, K., Yuasa‐Kawase, M., Tsubakio‐Yamamoto, K., Ohama, T., Nishida, M., Ishigami, M., et al. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02687.x · Cited by 59 · see citing works

Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice

Alipour, A., Valdivielso, P., Elte, J. W. F., Janssen, H. W., Rioja, J., van der Meulen, N., van Mechelen, R., Njo, T. L., González‐Santos, P., Rietveld, A. P., et al. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02635.x · Cited by 40 · see citing works

Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group

Stock, J. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.049 · Cited by 21 · see citing works

Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes

Hirose, T., Teramoto, T., Abe, K., Taneyama, T., & J-BENEFIT study group (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.27425 · Cited by 13 · see citing works

Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state

Irawati, D., Mamo, J. C. L., Soares, M. J., Clark, K., & James, A. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.018 · Cited by 6 · see citing works

Molecular Actions of PPARα in Lipid Metabolism and Inflammation

Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898 · see citing works

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749 · see citing works

Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease

Duran, E. K., Aday, A. W., Cook, N. R., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.059 · Cited by 336 · see citing works

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319 · see citing works

PPAR Agonists and Metabolic Syndrome: An Established Role?

Botta, M., Audano, M., Sahebkar, A., Sirtori, C. R., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253 · see citing works

Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study

Wadström, B. N., Wulff, A. B., Pedersen, K. M., Jensen, G. B., & Nordestgaard, B. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab705 · Cited by 234 · see citing works

Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases

Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191 · see citing works

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184 · see citing works

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164 · see citing works

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141 · see citing works

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140 · see citing works

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136 · see citing works

Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy

Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 114 · see citing works

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins

Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 85 · see citing works

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79 · see citing works

Lipid Lowering Drugs: Present Status and Future Developments

Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73 · see citing works

Synthetic Approaches to the New Drugs Approved During 2017

Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Helal, C. J., & O’Donnell, C. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00196 · Cited by 72 · see citing works

Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis

Hernández, P., Passi, N., Modarressi, T., Kulkarni, V., Soni, M., Burke, F., Bajaj, A., & Soffer, D. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00962-z · Cited by 74 · see citing works

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease

Kamata, S., Honda, A., & Ishii, I. (2023) · Biomolecules · doi:10.3390/biom13081264 · Cited by 67 · see citing works

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 68 · see citing works

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

Ida, S., Kaneko, R., & Murata, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0845-x · Cited by 61 · see citing works

Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, Main Text

Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61 · see citing works

Pemafibrate: First Global Approval

Blair, H. A. (2017) · Drugs · doi:10.1007/s40265-017-0818-x · Cited by 54 · see citing works

Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study

Zhu, L., Hayen, A. D., & Bell, K. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01002-x · Cited by 54 · see citing works

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia

Yamashita, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.06.010 · Cited by 51 · see citing works

High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine

Reijnders, E., van der Laarse, A., Jukema, J. W., & Cobbaert, C. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1264319 · Cited by 50 · see citing works

Fibrates in the management of atherogenic dyslipidemia

Okopień, B., Bułdak, Ł., & Bołdys, A. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1408410 · Cited by 49 · see citing works

Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy

Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48 · see citing works

Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes

Hermans, M. P., & Valensi, P. E. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000398 · Cited by 49 · see citing works

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

Yamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225537 · Cited by 48 · see citing works

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13686 · Cited by 46 · see citing works

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Yokote, K., Yamashita, S., Arai, H., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01291-w · Cited by 45 · see citing works

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

Matsuba, I., Matsuba, R., Ishibashi, S., Yamashita, S., Arai, H., Yokote, K., Suganami, H., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12845 · Cited by 44 · see citing works

Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy

Kanno, K., Koseki, M., Chang, J., Saga, A., Inui, H., Okada, T., Tanaka, K., Asaji, M., Zhu, Y., Ide, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06542-8 · Cited by 41 · see citing works

Activation of PPARs Modulates Signalling Pathways and Expression of Regulatory Genes in Osteoclasts Derived from Human CD14+ Monocytes

Kasonga, A. E., Kruger, M. C., & Coetzee, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071798 · Cited by 40 · see citing works

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 40 · see citing works

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate

Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., & Kodama, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225682 · Cited by 38 · see citing works

Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia

Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 39 · see citing works

PPARs in atherosclerosis: The spatial and temporal features from mechanism to druggable targets

Zheng, Y., Shao, M., Zheng, Y., Sun, W., Qin, S., Sun, Z., Zhu, L., Guan, Y., Wang, Q., Wang, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.020 · Cited by 37 · see citing works

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐ aspartate aminotransferase score

Hatanaka, T., Kosone, T., Saito, N., Takakusagi, S., Tojima, H., Naganuma, A., Takagi, H., Uraoka, T., & Kakizaki, S. (2021) · JGH Open · doi:10.1002/jgh3.12650 · Cited by 37 · see citing works

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease

Gabani, M. H., Shapiro, M. D., & Toth, P. P. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.16 · Cited by 38 · see citing works

Recent advances in synthetic pharmacotherapies for dyslipidaemias

Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34 · see citing works

Effects of resveratrol on lipid metabolism in liver of red tilapia Oreochromis niloticus

Zheng, Y., Shi, Y., Yang, X., Gao, J., Nie, Z., Song, L., Xu, G., & 邴旭文 (2022) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2022.109408 · Cited by 31 · see citing works

Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease

Ishii, J., Kashiwabara, K., Ozaki, Y., Takahashi, H., Kitagawa, F., Nishimura, H., Ishii, H., Iimuro, S., Kawai, H., Muramatsu, T., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63229 · Cited by 29 · see citing works

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study

Hatanaka, T., Kakizaki, S., Saito, N., Nakano, Y., Nakano, S., Hazama, Y., Yoshida, S., Hachisu, Y., Tanaka, Y., Kashiwabara, K., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6574-20 · Cited by 29 · see citing works

Chinese Herbs and Repurposing Old Drugs as Therapeutic Agents in the Regulation of Oxidative Stress and Inflammation in Pulmonary Diseases

Yang, C.-C., & Yang, C. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s293135 · Cited by 27 · see citing works

Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations

Kawasaki, M., Kambe, A., Yamamoto, Y., Arulmozhiraja, S., Ito, S., Nakagawa, Y., Tokiwa, H., Nakano, S., & Shimano, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010361 · Cited by 26 · see citing works

Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations

Lütjohann, D., Klör, H., & Stellaard, F. (2023) · Nutrients · doi:10.3390/nu15092202 · Cited by 25 · see citing works

Drugs targeting peroxisome proliferator-activated receptors

Xie, Z., Xin, J., Huang, C.-J., & Liao, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104318 · Cited by 22 · see citing works

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review

Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez‐Martínez, P., Mora, S., Bilianou, H. I., Panotopoulos, G., Katsiki, N., Ooi, T. C., López‐Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190503123911 · Cited by 22 · see citing works

Macrophage fatty acid oxidation in atherosclerosis

Xiao, S., Qi, M., Zhou, Q., Gong, H.-Q., Wei, D., Wang, G., Feng, Q., Wang, Z., Liu, Z., Zhou, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116092 · Cited by 22 · see citing works

Selective activation of PPARα by pemafibrate mitigates peritoneal inflammation and fibrosis through suppression of NLRP3 inflammasome and modulation of inflammation

Shinkai, Y., Sasaki, K., Tamura, R., Ike, T., Takahashi, A., Osaki, Y., Ishiuchi, N., Maeoka, Y., Nakashima, A., & Masaki, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-74340-5 · Cited by 19 · see citing works

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study

Nakamura, A., Kagaya, Y., Saito, H., Kanazawa, M., Sato, K., Miura, M., Kondo, M., & Endo, H. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63659 · Cited by 18 · see citing works

Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial

Doi, T., Langsted, A., & Nordestgaard, B. G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117556 · Cited by 23 · see citing works

New approaches to address dyslipidemia

Parhofer, K. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000456 · Cited by 19 · see citing works

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Fruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 18 · see citing works

Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury

Konishi, H., Miyauchi, K., Ōnishi, A., Suzuki, S., Fuchimoto, D., Shitara, J., Endo, H., Wada, H., Doi, S., Naito, R., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241195 · Cited by 18 · see citing works

Triglyceride-Rich Lipoproteins

Kockx, M., & Kritharides, L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.008 · Cited by 18 · see citing works

SPPARM alpha: the Lazarus effect

Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 16 · see citing works

Nonfasting TG/HDL-C ratio seems a good predictor of MACE in CAD patients with statin therapy. Could it be a treatment target?

Kiyosue, A. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.09.001 · Cited by 16 · see citing works

The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1094100 · Cited by 15 · see citing works

Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet

Yoshida, M., Nakamura, K., Miyoshi, T., Yoshida, M., Kondo, M., Akazawa, K., Kimura, T., Ohtsuka, H., Ohno, Y., Miura, D., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01132-2 · Cited by 15 · see citing works

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60764 · Cited by 14 · see citing works

How to Handle Elevated Triglycerides: Life after PROMINENT

Pirillo, A., & Catapano, A. L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01175-2 · Cited by 15 · see citing works

Studies on the regulation of lipid metabolism and the mechanism of the aqueous and ethanol extracts of Usnea

Zhu, J., Zhang, X., Chen, X., Sun, Y., Dai, Y., Chen, C., Zhang, T., & Yan, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.012 · Cited by 14 · see citing works

Triglyceride-lowering trials

KEECH, A. C., & Jenkins, A. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000465 · Cited by 14 · see citing works

Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?

Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14 · see citing works

Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr- deficient mice

Henry, D., Baugé, E., Hennuyer, N., Ory, K., Derudas, B., Vallez, E., Deprince, A., Lefèbvre, P., Haas, J. T., Staels, B., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adj8192 · Cited by 13 · see citing works

Drug Discovery for Coronary Artery Disease

Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13 · see citing works

Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial

Yamashita, S., Hirano, T., Shimano, H., Tsukamoto, K., Yoshida, M., & Yoshida, H. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14227 · Cited by 14 · see citing works

Tackling cardiometabolic risk in the Asia Pacific region

Li, J., Yeo, K. K., Tan, K., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Lam, C. S. P., Baek, S. H., Dalal, J. J., et al. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100096 · Cited by 12 · see citing works

The roles ofPPARsin human diseases

Li, J., & Liu, Y. (2018) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2018.1475673 · Cited by 11 · see citing works

Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR-α modulator for treatment of combined dyslipidemia

Camejo, G. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.013 · Cited by 11 · see citing works

Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review

Khan, M. S., Ghumman, G. M., Baqi, A., Shah, J., Aziz, M., Mir, T., Tahir, A., Katragadda, S., Singh, H., Taleb, M., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00593-6 · Cited by 11 · see citing works

Correction to: Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet

Yoshida, M., Nakamura, K., Miyoshi, T., Yoshida, M., Kondo, M., Akazawa, K., Kimura, T., Ohtsuka, H., Ohno, Y., Miura, D., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01181-7 · Cited by 10 · see citing works

Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate

Wang, H., Li, H., Zhou, Y., Liu, J., Wang, F., & Zhao, Q. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191126102943 · Cited by 11 · see citing works

High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 9 · see citing works

Effect of Novel Stratified Lipid Risk by “LDL-Window” and Flow-Mediated Dilation on the Prognosis of Coronary Artery Disease Using the FMD-J Study A Data

Abe, S., Haruyama, Y., Kobashi, G., Toyoda, S., Inoue, T., Tomiyama, H., Ishizu, T., Kohro, T., Higashi, Y., Takase, B., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-1068 · Cited by 9 · see citing works

Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial

Arai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Yamasaki, S., Suganami, H., & Ishibashi, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64677 · Cited by 8 · see citing works

Discordance of Small Dense LDL Cholesterol Beyond LDL Cholesterol or Non–HDL Cholesterol and Carotid Plaque

Wang, J., Zhao, X., Zhao, Y., Jin, R., Li, Y., Wang, J., Liu, Y., Wu, Z., Guo, X., & Tao, L. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.04.015 · Cited by 7 · see citing works

The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors

Kusunoki, M., Sakazaki, T., Tsutsumi, K., Miyata, T., & Oshida, Y. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320999200818135553 · Cited by 7 · see citing works

Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature

Brogi, S., Tabanelli, R., & Calderone, V. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2104247 · Cited by 7 · see citing works

Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies

Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 8 · see citing works

Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects

Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7 · see citing works

Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease

Takata, K., Kataoka, Y., Andrews, J., Puri, R., Hammadah, M., Duggal, B., Kapadia, S. R., Tuzcu, E. M., Nissen, S. E., & Nicholls, S. J. (2018) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.02.017 · Cited by 7 · see citing works

Selective PPARα Modulator (SPPARMα) in the Era of the MASLD Pandemic: Current Insights and Future Prospects

Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8 · see citing works

The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications

Gupta, A., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113758 · Cited by 7 · see citing works

[HDL‐C/apoA‐I]: A multivessel cardiometabolic risk marker in women with T2DM

Hermans, M. P., Valensi, P. E., Ahn, S. A., & Rousseau, M. F. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2950 · Cited by 6 · see citing works

The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk–reducing therapies to the novel challenging strategies

Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5 · see citing works

Study protocol of the PROUD48 study comparing the effects of pemafibrate and omega-3 fatty acid ethyl esters on ApoB-48 in statin-treated patients with dyslipidaemia: a prospective, multicentre, open-label, randomised, parallel group trial in Japan

Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061360 · Cited by 4 · see citing works

Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study

Katakura, Y., Shimoda, M., Ohnishi, M., Kusano, T., Dan, K., Isobe, H., Wamata, R., Iwamoto, Y., Fushimi, Y., Sanada, J., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.02.011 · Cited by 5 · see citing works

Fibrates : Do They Still Have a Role in Therapy in 2025?

Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4 · see citing works

Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio

Imamura, T., Narang, N., & Kinugawa, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102820 · Cited by 5 · see citing works

Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome

Iwakura, T., Yasu, T., Tomoe, T., Ueno, A., Sugiyama, T., Otani, N., Kawamoto, S., & Nakajima, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041481 · Cited by 4 · see citing works

Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia

Hida, Y., Imamura, T., & Kinugawa, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216915 · Cited by 5 · see citing works

Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies

Kamimura, T., Hounslow, N. J., Suganami, H., & Tanigawa, R. (2024) · Clinical and Translational Science · doi:10.1111/cts.13900 · Cited by 4 · see citing works

Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline

Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4 · see citing works

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs

Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4 · see citing works

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice

Iitake, C., & Iitake, K. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3949 · Cited by 4 · see citing works

Investigational drugs in development for hypertriglyceridemia: a coming-of-age story

Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4 · see citing works

Abstract 13374: Efficacy and Safety of K-877, a Potent and Selective PPAR-α Modulator (SPPARMα), in Combination With Statins in Japanese Patients With Dyslipidemia

Arai, H., Ishibashi, S., Yamashita, S., Araki, E., Yokote, K., Suganami, H., & Kodama, T. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.13374 · Cited by 6 · see citing works

Abstract 12384: Novel Approach to Residual Risk, K-877, a Potent and Selective PPAR-α Modulator (SPPARMα), Added-on to Pitavastatin in Japanese Patients With Dyslipidemia

Yokote, K., Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Kodama, T. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.12384

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208 · see citing works

Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy

Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48 · see citing works

Abstract 10718: Efficacy and Safety of K-877, a Potent and Selective PPAR-a Agonist, in Japanese Patients With Dyslipidemia

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., & Kodama, T. (2013) · Circulation